

**Table S4.** Prevalence of PIM category IV (n=22,099)

Object + interacting drug/class <sup>a)</sup>	PIM category IV <sup>b)</sup>	n (%)	Number of times PIM prescribed
Anticholinergics + anticholinergics (n = 2,061; 9.33%)	Amitriptyline + orphenadrine	783 (3.54)	1 (1–2)
	Dimenhydrinate + orphenadrine	496 (2.24)	1 (1–1)
	Hydroxyzine + orphenadrine	283 (1.28)	1 (1–2)
	Chlorpheniramine + orphenadrine	144 (0.65)	1 (1–1)
	Amitriptyline + dimenhydrinate	140 (0.63)	1 (1–1)
Corticosteroids (oral or parenteral) + NSAIDs (n = 467; 2.11%)	Prednisolone + aspirin low dose	113 (0.51)	2 (1–6)
	Prednisolone + naproxen	111 (0.50)	1 (1–3)
	Triamcinolone + naproxen	100 (0.45)	1 (1–1)
	Dexamethasone + naproxen	74 (0.33)	1 (1–1)
	Triamcinolone + celecoxib	41 (0.19)	1 (1–1)
A combination of three or more CNS-active drugs (n = 449; 2.03%)	Amitriptyline + sertraline + lorazepam	51 (0.23)	4 (1–11)
	Amitriptyline + fluoxetine + lorazepam	48 (0.22)	8.5 (3–10)
	Sertraline + clonazepam + lorazepam	43 (0.19)	5 (2–11)
	Sertraline + lorazepam + diazepam	42 (0.19)	5 (2–9)
	Sertraline + alprazolam + lorazepam	38 (0.17)	5.5 (1–10)
Opioids + gabapentin (n = 428; 1.94%)	Tramadol + gabapentin	393 (1.78)	1 (1–2)
	Morphine + gabapentin	41 (0.19)	1 (1–1)
	Codeine + gabapentin	17 (0.08)	1 (1–2)
	Pethidine + gabapentin	7 (0.03)	1 (1–1)
	Fentanyl + gabapentin	6 (0.03)	2.5 (1–9)
Opioids + benzodiazepines (n = 333; 1.51%)	Tramadol + lorazepam	223 (1.01)	1 (1–2)
	Morphine + lorazepam	42 (0.19)	1 (1–3)
	Tramadol + diazepam	31 (0.14)	1 (1–1)
	Pethidine + diazepam	23 (0.10)	1 (1–1)
	Tramadol + clonazepam	21 (0.10)	1 (1–3)
Peripheral $\alpha$ -1 blockers + loop diuretics (n = 306; 1.38%)	Doxazosin + furosemide	299 (1.35)	4 (2–7)
	Prazosin + furosemide	7 (0.03)	4 (3–6)
RAS inhibitors/potassium-sparing diuretics + another RAS inhibitors (n = 72; 0.33%)	Enalapril + captopril	22 (0.10)	1 (1–1)
	Captopril + losartan	18 (0.08)	1 (1–1)
	Enalapril + amiloride	15 (0.07)	3 (2–6)
	Losartan + amiloride	15 (0.07)	5 (3–7)
Warfarin + NSAIDs (n = 64; 0.29%)	Warfarin + low dose aspirin	64 (0.29)	5 (2–9)
Theophylline + ciprofloxacin (n = 7; 0.03%)	Theophylline + ciprofloxacin	7 (0.03)	1 (1–2)
Warfarin + macrolides (exclude azithromycin) (n = 7; 0.03%)	Warfarin + roxithromycin	5 (0.02)	1 (1–1)
	Warfarin + clarithromycin	2 (0.01)	2 (1–3)
Warfarin + amiodarone (n = 5; 0.02%)	Warfarin + amiodarone	5 (0.02)	1 (1–6)
Warfarin + ciprofloxacin (n = 3; 0.015%)	Warfarin + ciprofloxacin	3 (0.015)	1 (1–8)
Warfarin + trimethoprim-sulfamethoxazole (n = 1; 0.005%)	Warfarin + trimethoprim-sulfamethoxazole	1 (0.005)	6 (6–6)
Overall prevalence 15.66% (n = 3,460)			

Values are presented as number (%) or median (interquartile range).

PIM, potentially inappropriate medication; NSAIDs, non-steroidal anti-inflammatory drugs; CNS, central nervous system; RAS, renin-angiotensin system.

<sup>a)</sup>Listed in descending order of frequency.

<sup>b)</sup>For each drug-drug interaction, the five most prescribed PIMs are listed in descending order of frequency.